PCR-based screening services for CRISPR/Cas9-generated models quickly and accurately identifies which founders or cell lines carry mutations with small INDELS at the intended targeting site. Our PCR analysis platform based on microfluidic, laser-induced fluorescence technology allows sensitive detection of heteroduplex formation when small INDELs are present, which is the basis for T7 endonuclease digestion, the most commonly used screening method for CRISPR/Cas9 generated mutations. This PCR platform combined with our proprietary assays produce cleaner data compared to T7 digestion, which often produces background noise, making mutation detection ambiguous.

CRISPR-Cas9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.